Boston Scientific Trial Wins Highlight Growth Potential In Electrophysiology And Stroke Care

Boston Scientific (NYSE:BSX) released new clinical trial results for its FARAPULSE PFA Platform and WATCHMAN LAAC at Heart ...
The Daily Tribune News

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in ...
MassDevice

Boston Scientific studies back Farawave, Faraflex, Watchman FLX Pro and more

Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.
Morningstar

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
Nasdaq

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...